A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Due to Distal [M2 Segment and Beyond] Arterial Large Vessel Occlusion (LVO) or Perforator Occlusion and Who Are Ineligible for Intravenous Thrombolysis (IVT) or Endovascular Thrombectomy (EVT)
Latest Information Update: 13 Apr 2023
At a glance
- Drugs Afamelanotide (Primary)
- Indications Ischaemic stroke
- Focus Adverse reactions; Proof of concept
- Acronyms CUV801
- Sponsors Clinuvel Pharmaceuticals
Most Recent Events
- 03 May 2022 Positive final results published in the Clinuvel Pharmaceuticals Media Release.
- 22 Feb 2022 Status changed from active, no longer recruiting to completed.
- 18 Jan 2022 Planned End Date changed from 1 Jun 2022 to 1 Feb 2022.